Fase 2-studie til vurdering af sikkerhed og effekt af ANG003
En fase 2, multicenter, randomiseret, aktiv-kontrolleret undersøgelse for at vurdere sikkerheden og effektiviteten af ANG003 ved to forskellige doseringsniveauer hos personer med exokrin pankreasinsufficiens på grund af cystisk fibrose
In this study, ANG003, a pancreatic enzyme replacement therapy (PERT; commonly called "enzymes"), is being investigated as a potential treatment for exocrine pancreatic insufficiency (EPI). People with EPI due to Cystic Fibrosis (CF) may be eligible to participate in this study. The primary objective of this study is to evaluate the safety of ANG003 and see if it works as well compared to Creon, an approved PERT.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 2
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Evan Bailey, MD
- Telefonnummer: 617-466-3111
- E-mail: medical@anagramtx.com
Studiesteder
-
-
California
-
Long Beach, California, Forenede Stater, 90806
- Rekruttering
- Long Beach Memorial Medical Center
-
Kontakt:
- Angelica Rodriguez
- Telefonnummer: 562-706-1245
- E-mail: ARodriguez9@memorialcare.org
-
Los Angeles, California, Forenede Stater, 90033
- Rekruttering
- Center for Cystic Fibrosis at Keck Medical Center of USC
-
Kontakt:
- Lynn Fukushima
- Telefonnummer: 323-442-8522
- E-mail: lynn.fukushima@med.usc.edu
-
-
Colorado
-
Denver, Colorado, Forenede Stater, 80206
- Rekruttering
- National Jewish Health
-
Kontakt:
- Alix Wilson
- Telefonnummer: 303-270-2517
- E-mail: wilsona@njhealth.org
-
-
Florida
-
Gainesville, Florida, Forenede Stater, 32610
- Ikke rekrutterer endnu
- University of Florida
-
Kontakt:
- Alexa Smith
- Telefonnummer: 352-273-8380
- E-mail: alexa.howell@ufl.edu
-
Orlando, Florida, Forenede Stater, 32803
- Ikke rekrutterer endnu
- Central Florida Pulmonary Group
-
Kontakt:
- Desiree Serr
- Telefonnummer: 407-303-7192
- E-mail: desiree.serr1@adventhealth.com
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30324
- Rekruttering
- Emory-Children's Healthcare of Atlanta Cystic Fibrosis Center
-
Kontakt:
- Eric Hunter
- Telefonnummer: 678-977-5212
- E-mail: eahunte@emory.edu
-
-
Illinois
-
Glenview, Illinois, Forenede Stater, 60025
- Rekruttering
- The Cystic Fibrosis Institute
-
Kontakt:
- Steven R Boas, MD
- Telefonnummer: 847-998-3434
- E-mail: sboas@wecare4lungs.com
-
-
Iowa
-
Iowa City, Iowa, Forenede Stater, 52242
- Ikke rekrutterer endnu
- University of Iowa
-
Kontakt:
- Mary Teresi
- Telefonnummer: 319-384-7546
- E-mail: mary-teresi@uiowa.edu
-
-
Kansas
-
Kansas City, Kansas, Forenede Stater, 66160
- Rekruttering
- University of Kansas Medical Center
-
Kontakt:
- Lawrence Scott
- Telefonnummer: 913-588-4020
- E-mail: lscott2@kumc.edu
-
-
Kentucky
-
Lexington, Kentucky, Forenede Stater, 40506
- Rekruttering
- University of Kentucky
-
Kontakt:
- Chase Whitaker
- Telefonnummer: 859-218-4810
- E-mail: chase.whitaker@uky.edu
-
-
Maine
-
Portland, Maine, Forenede Stater, 04102
- Ikke rekrutterer endnu
- MaineHealth Pediatric Specialty Care
-
Kontakt:
- Rebecca Edwards
- Telefonnummer: 207-662-6712
- E-mail: rebecca.edwards@mainehealth.org
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02114
- Rekruttering
- Massachusetts General Hospital
-
Kontakt:
- Margot Hardcastle
- Telefonnummer: 617-726-3719
- E-mail: mhardcastle@mgh.harvard.edu
-
Boston, Massachusetts, Forenede Stater, 02115
- Rekruttering
- Boston Children's Hospita
-
Kontakt:
- Robert Fowler
- Telefonnummer: 617-355-1834
- E-mail: Robert.fowler@childrens.harvard.edu
-
-
Michigan
-
Ann Arbor, Michigan, Forenede Stater, 48109
- Rekruttering
- University of Michigan, Michigan Medicine
-
Kontakt:
- Dawn Kruse
- Telefonnummer: 734-615-3266
- E-mail: dmkruse@med.umich.edu
-
Detroit, Michigan, Forenede Stater, 48201
- Rekruttering
- Wayne State University Harper University Hospital
-
Kontakt:
- Debra Driscoll
- Telefonnummer: 313-745-2221
- E-mail: ddriscol@med.wayne.edu
-
-
Minnesota
-
Minneapolis, Minnesota, Forenede Stater, 55455
- Rekruttering
- University of Minnesota
-
Kontakt:
- Brooke Noren, RN, BSN, CCRC
- Telefonnummer: 612-625-7995
- E-mail: boer0039@umn.edu
-
-
New Jersey
-
New Brunswick, New Jersey, Forenede Stater, 08903
- Rekruttering
- Rutgers - Robert Wood Johnson Medical School
-
Kontakt:
- Sheila Redding
- Telefonnummer: 732-235-7840
- E-mail: sr1238@rwjms.rutgers.edu
-
-
New York
-
Valhalla, New York, Forenede Stater, 10595
- Ikke rekrutterer endnu
- New York Medical College at Westchester Medical Center
-
Kontakt:
- Zachary Messer
- Telefonnummer: 914-594-2352
- E-mail: Zachary_Messer@nymc.edu
-
-
Ohio
-
Akron, Ohio, Forenede Stater, 44308
- Rekruttering
- Children's Hospital Medical Center of Akron
-
Kontakt:
- Michelle Parrish
- Telefonnummer: 330-543-3089
- E-mail: MParrish@akronchildrens.org
-
Cleveland, Ohio, Forenede Stater, 44106
- Rekruttering
- Rainbow Babies and Children's Hospital/University Hospitals Cleveland Medical Center
-
Kontakt:
- Primary RC & Participant Contact General Contact
- Telefonnummer: 216-844-3911
- E-mail: RainbowCFResearch@UHhospitals.org
-
Columbus, Ohio, Forenede Stater, 43205
- Rekruttering
- Nationwide Children's Hospital, Columbus
-
Kontakt:
- Diana Gilmore
- Telefonnummer: 614-722-4752
- E-mail: diana.gilmore@nationwidechildrens.org
-
Toledo, Ohio, Forenede Stater, 43606
- Rekruttering
- Toledo Children's Hospital
-
Kontakt:
- Kelly Hoot
- Telefonnummer: 419-291-4630
- E-mail: kelly.hoot@promedica.org
-
-
Pennsylvania
-
Hershey, Pennsylvania, Forenede Stater, 17033
- Rekruttering
- Hershey Medical Center Pennsylvania State University
-
Kontakt:
- Diane Kitch
- Telefonnummer: 717-531-5646
- E-mail: dkitch@pennstatehealth.psu.edu
-
Pittsburgh, Pennsylvania, Forenede Stater, 15224
- Ikke rekrutterer endnu
- University of Pittsburgh Medical Center
-
Kontakt:
- Adrienne DeRicco
- Telefonnummer: 412-692-8069
- E-mail: adrienne.dericco2@upmc.edu
-
-
Texas
-
Dallas, Texas, Forenede Stater, 75207
- Rekruttering
- University of Texas Southwestern / Children's Health
-
Kontakt:
- Keianna Brown
- Telefonnummer: 214-456-5489
- E-mail: Keianna.brown@utsouthwestern.edu
-
-
Utah
-
Salt Lake City, Utah, Forenede Stater, 84112
- Rekruttering
- Adult Cystic Fibrosis Center at the University of Utah
-
Kontakt:
- Kristyn Packer
- Telefonnummer: 801-520-5106
- E-mail: kristyn.packer@hsc.utah.edu
-
-
Wisconsin
-
Madison, Wisconsin, Forenede Stater, 53792
- Rekruttering
- University of Wisconsin
-
Kontakt:
- Melanie Nelson
- Telefonnummer: 608-265-4617
- E-mail: mnelson@pediatrics.wisc.edu
-
Milwaukee, Wisconsin, Forenede Stater, 53226
- Ikke rekrutterer endnu
- Froedtert & Medical College of Wisconsin
-
Kontakt:
- Erin Hubertz
- Telefonnummer: 414-955-7019
- E-mail: ehubertz@mcw.edu
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
-
Male and female subjects aged ≥12 years from the date of informed consent in the US and aged ≥18 years in the EU
-
Confirmed and documented diagnosis of CF
-
Diagnosed with severe EPI as defined by a fecal elastase ≤50 μg/g stool measured at Screening by a central laboratory.
-
Subject has controlled EPI and taking a stable dose of pancreatic enzyme replacement therapy (PERT) for 90 days prior to Screening.
-
Adequate nutritional status measured by body mass index (BMI) defined by:
- BMI ≥25th percentile for children aged 12-17 years
- BMI ≥18.5 kg/m2 for ≥18 years of age
Exclusion Criteria:
- History of fibrosing colonopathy or recurring distal intestinal obstructive syndrome within 6 months of Screening.
- History of lung or liver transplant, listing for organ transplant or significant bowel resection within the last 6 months. Subjects with a history of resection that does not result in short bowel syndrome are eligible.
- Known hypersensitivity or other severe reaction to any ingredient of the investigational product (IP), Creon, or the stool marker (FD&C Blue #2).
- Any chronic diarrheal illness unrelated to pancreatic insufficiency, actively being treated for small intestinal bacterial overgrowth, requiring use of naso-gastric, J-tube, G-tube, and/or enteral feeding for the study duration, Clostridioides difficile infection within 6 months prior to Screening, or severe constipation defined as <1 bowel movement/week.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Enkelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: ANG003 Dose A
All subjects will be acclimated to Creon for 14-days and then will undergo a baseline CFA analysis. If baseline CFA is >/= 80%, the subject may be randomized to ANG003 Dose A for a 21-day acclimation and subsequent CFA analysis. |
160,000 u* lipase, 105,000 u* protease, and 11,600 u* amylase per dose (*units are comparable to United States Pharmacopeiea [USP]) |
|
Eksperimentel: ANG003 Dose B
All subjects will be acclimated to Creon for 14-days and then will undergo a baseline CFA analysis. If baseline CFA is >/= 80%, the subject may be randomized to ANG003 Dose B for a 21-day acclimation and subsequent CFA analysis. |
240,000 u* lipase, 105,000 u* protease, and 11,600 u* amylase per dose (*units are comparable to United States Pharmacopeiea [USP]) |
|
Aktiv komparator: Creon
All subjects will be acclimated to Creon for 14-days and then will undergo a baseline CFA analysis. If baseline CFA is >/= 80%, the subject may be randomized to Creon for an additional 21-days and subsequent CFA analysis. |
The commercially available pPERT Creon will be the active comparator in the study. Subjects will be instructed to take Creon according to the package insert and PI direction. |
|
Ingen indgriben: Off Enzyme
All subjects will be acclimated to Creon for 14-days and then will undergo a baseline CFA analysis. If baseline CFA is >/= 80%, the subject may be randomized to the off enzyme arm. Subjects will receive Creon for an additional 21-day and the subsequent CFA analysis will be off enzyme. Total time off enzyme will be 4-7 days. |
|
|
Andet: 60% to <80% CFA ANG003 Dose B
All subjects will be acclimated to Creon for 14-days and then will undergo a baseline CFA analysis. Participants with a Period A CFA result of 60% to <80% will be assigned to ANG003 Dose B. |
240,000 u* lipase, 105,000 u* protease, and 11,600 u* amylase per dose (*units are comparable to United States Pharmacopeiea [USP]) |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Adverse events (AEs); Treatment-emergent AEs; Serious AEs; Discontinuation due to AEs; Clinical laboratory values
Tidsramme: From Visit 1 to Visit 5, anticipated average 80 days
|
Adverse events (AEs); Treatment-emergent AEs; Serious AEs; Discontinuation due to AEs; Clinical laboratory values |
From Visit 1 to Visit 5, anticipated average 80 days
|
|
Coefficient of Fat Absorption (CFA)
Tidsramme: Period A (baseline) and Period B 72 hour CFA collection
|
Mean change from baseline CFA (i.e., Period B CFA minus Period A CFA) assessed for ANG003 Dose A, ANG003 Dose B, and Creon amongst subjects with baseline CFA ≥80%. |
Period A (baseline) and Period B 72 hour CFA collection
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Plasma docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) (ug/mL)
Tidsramme: Period A (baseline) and Period B time 0, 1, 2, 4, 6, 8, 10 and 24 hour collections
|
Mean change from baseline for each treatment group amongst subjects with baseline CFA ≥80%. |
Period A (baseline) and Period B time 0, 1, 2, 4, 6, 8, 10 and 24 hour collections
|
|
Coefficient of Nitrogen Absorption (CNA)
Tidsramme: Period A (baseline) and Period B 72 hour CNA collection
|
Mean change from baseline for each treatment group amongst subjects with baseline CFA ≥80%. |
Period A (baseline) and Period B 72 hour CNA collection
|
|
% of subjects with GI symptoms
Tidsramme: From Visit 2 to Visit 5, anticipated average 59 days
|
Mean change from baseline for each treatment group amongst subjects with baseline CFA ≥80%. |
From Visit 2 to Visit 5, anticipated average 59 days
|
|
Cumulative stool weight
Tidsramme: Period A (baseline) and Period B 72 hour collection
|
Mean change from baseline for each treatment group amongst subjects with baseline CFA ≥80%. |
Period A (baseline) and Period B 72 hour collection
|
|
Number of Stools per Day
Tidsramme: Period A (baseline) and Period B 72 hour collection
|
Mean change from baseline for each treatment group amongst subjects with baseline CFA ≥80%. |
Period A (baseline) and Period B 72 hour collection
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Correlation between DHA/EPA and CFA
Tidsramme: Period A (baseline) Period B 72 hour CFA and 24 hour DHA/EPA collection
|
Mean change from baseline for each treatment group with a baseline CFA ≥80% |
Period A (baseline) Period B 72 hour CFA and 24 hour DHA/EPA collection
|
|
Coefficient of Fat Absorption (CFA) for subjects with a baseline CFA of 60% to <80% (analyzed separately)
Tidsramme: Period A (baseline) and Period B 72 hour CFA collection
|
Mean change from baseline for each treatment group with a baseline CFA 60% to <80% |
Period A (baseline) and Period B 72 hour CFA collection
|
|
Mean Period B CFA for all subjects randomized to the Off Enzyme arm with a baseline CFA ≥80%
Tidsramme: Period B 72 hour CFA collection
|
Period B CFA Off Enzyme in subjects with a baseline CFA ≥80% |
Period B 72 hour CFA collection
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Genetiske sygdomme, medfødte
- Luftvejssygdomme
- Sygdomme i fordøjelsessystemet
- Lungesygdomme
- Spædbarn, Nyfødt, Sygdomme
- Pancreassygdomme
- Medfødte, arvelige og neonatale sygdomme og abnormiteter
- Cystisk fibrose
- Eksokrin pancreasinsufficiens
- Hydrolaser
- Enzymer
- Enzymer og coenzymer
- Komplekse blandinger
- Lipase
- Carboxyliske esterhydrolaser
- Esteraser
- Pankreatiske ekstrakter
- Vævsekstrakter
- Pancrelipase
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- ANG003-25-201
- 2025-524569-25-00 (Ctis)
- 2025 (U.S. NIH-bevilling/kontrakt)
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .